| Date | Title | Description |
| 20.05.2025 | Aptahem receives strong interest in partnership from a European pharmaceutical company | Aptahem receives strong interest in partnership from a European pharmaceutical company
Tue, May 20, 2025 16:20 CET Report this content
Aptahem AB (publ), a biotechnology company developing RNA-based therapies for serious inflammatory condit... |
| 14.04.2025 | Aptahem Initiates Strategic Collaboration with Hongene Biotech to further reduce Manufacturing Costs and Enhance Sustainability for Lead Drug Candidate Apta-1 | Aptahem Initiates Strategic Collaboration with Hongene Biotech to further reduce Manufacturing Costs and Enhance Sustainability for Lead Drug Candidate Apta-1
Mon, Apr 14, 2025 10:07 CET Report this content
Aptahem AB (publ), a biotech comp... |
| 01.04.2025 | BioStock Article: Aptahem reports growing buzz around Apta-1 | BioStock Article: Aptahem reports growing buzz around Apta-1
Tue, Apr 01, 2025 19:14 CET Report this content
Malmö-based Aptahem recently released detailed plans of their upcoming phase II study with candidate Apta-1, set to prove its multi... |
| 28.03.2025 | Wyld Networks: A New Dawn in Connectivity | In the vast landscape of technology, Wyld Networks is carving a niche. The company is not just another player; it’s a beacon of innovation in wireless connectivity. Their recent interim report for Q4 2024 reveals a story of resilience and a... |
| 26.03.2025 | Mangold Insight’s CEO Interview follows up on previous interview from BIO Europe Spring | Mangold Insight’s CEO Interview follows up on previous interview from BIO Europe Spring
Wed, Mar 26, 2025 15:25 CET Report this content
Mangold Insight recently published an interview with Aptahem’s CEO Mikael Lindstam. The interview follow... |
| 15.03.2025 | Aptahem's Bold Leap into Clinical Trials: A New Dawn for Apta-1 | Aptahem AB is gearing up for a significant milestone in the world of biotechnology. The company is set to launch a Phase 2 clinical study for its promising drug candidate, Apta-1. This innovative treatment aims to tackle acute urogenital an... |
| 13.03.2025 | Aptahem presents plan for upcoming patient study | Aptahem presents plan for upcoming patient study
Thu, Mar 13, 2025 13:21 CET Report this content
Aptahem AB (publ) announces today a synopsis for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed ... |
| 11.03.2025 | Newsletter March 2025 | Newsletter March 2025
Tue, Mar 11, 2025 15:18 CET Report this content
CEO comments
We have now entered 2025 with high energy and a clear focus on driving Aptahem forward. The interest in RNA-related medicines continues to grow and we see in... |
| 13.02.2025 | Aptahem receives patent protection in South Korea for patent family 2 | Aptahem receives patent protection in South Korea for patent family 2
Thu, Feb 13, 2025 19:42 CET Report this content
Aptahem AB (publ) announces today that the company has received patent protection (Notice of Patent Grant) in South Korea ... |
| 10.12.2024 | Aptahem's Scientific Manuscript now Published in the British Journal of Pharmacology | Aptahem's Scientific Manuscript now Published in the British Journal of Pharmacology
Tue, Dec 10, 2024 13:44 CET Report this content
Aptahem announced on 10 September 2024 that their scientific manuscript had been accepted for publication i... |
| 22.10.2024 | Aptahem enters strategic collaboration agreement with e-Projection to more efficiently achieve partnership in Japan | Aptahem enters strategic collaboration agreement with e-Projection to more efficiently achieve partnership in Japan
Tue, Oct 22, 2024 16:22 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suff... |
| 10.09.2024 | Aptahem's Scientific Collaboration on Apta-1’s Mechanism of Action Accepted for Publication in the British Journal of Pharmacology | Aptahem's Scientific Collaboration on Apta-1’s Mechanism of Action Accepted for Publication in the British Journal of Pharmacology
Tue, Sep 10, 2024 14:05 CET Report this content
Aptahem announced today that their scientific collaboration w... |
| 02.09.2024 | Aptahem comments on interesting data after finalised phase 1 study | Aptahem comments on interesting data after finalised phase 1 study
Mon, Sep 02, 2024 09:42 CET Report this content
Aptahem AB (publ), a biotechnology company developing treatments for patients suffering from acute inflammatory diseases such... |
| 16.08.2024 | Aptahem receives patent protection in Israel for patent family 2 | Aptahem receives patent protection in Israel for patent family 2
Fri, Aug 16, 2024 17:48 CET Report this content
Aptahem AB (publ) announces today that the company has received patent protection in Israel for patent family 2 from the Israel... |
| 27.06.2024 | Aptahem reports the FIH study on Apta-1 has been finalized | Aptahem reports the FIH study on Apta-1 has been finalized
Thu, Jun 27, 2024 15:22 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, to... |
| 18.04.2024 | Aptahem plans to perform a Proof-of-Concept Phase 2 study in patients with its lead candidate Apta-1 | Aptahem plans to perform a Proof-of-Concept Phase 2 study in patients with its lead candidate Apta-1
Thu, Apr 18, 2024 08:29 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acut... |
| 27.03.2024 | Aptahem reports top line results from the FIH study with Apta-1 | Aptahem reports top line results from the FIH study with Apta-1
Wed, Mar 27, 2024 11:58 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsi... |
| 04.03.2024 | Aptahem’s CSO to present at Biologics World Nordics Conference | Aptahem’s CSO to present at Biologics World Nordics Conference
Mon, Mar 04, 2024 16:40 CET Report this content
Aptahem’s CSO Dr Luiza Jedlina has been invited to speak at the Biologics World Nordics conference in Copenhagen on 7 March 2024.... |
| 28.02.2024 | Aptahem’s scientific manuscript now published in the journal Cells | Aptahem’s scientific manuscript now published in the journal Cells
Wed, Feb 28, 2024 14:40 CET Report this content
Aptahem announced on the 27 February 2024 that the company’s scientific manuscript had been accepted for publication in the j... |
| 27.02.2024 | Aptahem’s scientific manuscript in collaboration with the research group at UHN in Toronto has been approved for publication in the journal Cells | Aptahem’s scientific manuscript in collaboration with the research group at UHN in Toronto has been approved for publication in the journal Cells
Tue, Feb 27, 2024 16:52 CET Report this content
The ground-breaking results from the studies p... |
| 05.01.2024 | Aptahem receives Notice of Allowance in Israel for patent family 2 | Aptahem receives Notice of Allowance in Israel for patent family 2
Fri, Jan 05, 2024 08:30 CET Report this content
Aptahem AB (publ) announces today that the company has received a Notice of Allowance in Israel of the patent application no ... |
| 09.11.2023 | Aptahem finalizes Part 1a of the FIH study for its lead candidate Apta-1 | Aptahem finalizes Part 1a of the FIH study for its lead candidate Apta-1
Thu, Nov 09, 2023 16:46 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such... |
| 15.09.2023 | Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study | Aptahem reports promising outcome from the additional analyses on the mechanism on lead candidate Apta-1 in the FIH study
Fri, Sep 15, 2023 08:27 CET Report this content
Aptahem AB (publ) announces today that the results from the additional... |
| 05.09.2023 | Aptahem attends the BioStock Investor Meeting on 20 September 2023 | Aptahem attends the BioStock Investor Meeting on 20 September 2023
Tue, Sep 05, 2023 15:20 CET Report this content
Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, whic... |
| 05.09.2023 | BioStock article: Aptahem's CEO comments on Q2 and looks ahead | BioStock article: Aptahem's CEO comments on Q2 and looks ahead
Tue, Sep 05, 2023 09:17 CET Report this content
For Aptahem, the second quarter continued to focus on the clinical development of drug candidate Apta-1 against sepsis. However, ... |
| 24.07.2023 | BioStock-article: Aptahem comments on the paused phase I study | BioStock-article: Aptahem comments on the paused phase I study
Mon, Jul 24, 2023 15:49 CET Report this content
Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phas... |
| 17.07.2023 | In Aptahem’s FIH study further analytic studies will be performed | In Aptahem’s FIH study further analytic studies will be performed
Mon, Jul 17, 2023 08:45 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sep... |
| 27.06.2023 | Aptahem’s poster presented at the ISTH conference now available | Aptahem’s poster presented at the ISTH conference now available
Tue, Jun 27, 2023 09:10 CET Report this content
Aptahem participates in the conference International Society on Thrombosis and Haemostasis (ISTH) on 24-28 June where CSO Dr Lui... |
| 21.06.2023 | BioStock article: Aptahem gives update on operations and rights issue | BioStock article: Aptahem gives update on operations and rights issue
Wed, Jun 21, 2023 09:01 CET Report this content
Aptahem is making strides in the field of sepsis treatment with its drug candidate Apta-1. Recently, the company announced... |
| 01.06.2023 | Aptahem’s presentation at the BioStock Life Science Summit now available | Aptahem’s presentation at the BioStock Life Science Summit now available
Thu, Jun 01, 2023 11:46 CET Report this content
Aptahem’s CEO Mikael Lindstam presented the company and gave an update on the ongoing activities at the BioStock Life S... |
| 31.05.2023 | Fourth cohort completed in Aptahem’s FIH study | Fourth cohort completed in Aptahem’s FIH study
Wed, May 31, 2023 09:44 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces toda... |
| 29.05.2023 | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31! | Find your next investment at the BioStock Life Science Spring Summit on May 30 and 31!
Mon, May 29, 2023 09:45 CET Report this content
It is finally time for BioStock Life Science Spring Summit 2023! Around 30 companies from a wide range of... |
| 26.05.2023 | Aptahem attends the BioStock Life Science Summit on 31 May 2023 | Aptahem attends the BioStock Life Science Summit on 31 May 2023
Fri, May 26, 2023 10:57 CET Report this content
Aptahem’s CEO Mikael Lindstam is presenting the company and gives an update on the ongoing activities. The presentation, which i... |
| 28.04.2023 | BioStock article: Aptahem on the need for more effective sepsis treatments | BioStock article: Aptahem on the need for more effective sepsis treatments
Fri, Apr 28, 2023 14:38 CET Report this content
Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality an... |
| 31.03.2023 | BioStock article: Aptahem’s CEO sees continued interest in Apta-1 | BioStock article: Aptahem’s CEO sees continued interest in Apta-1
Fri, Mar 31, 2023 10:49 CET Report this content
Aptahem is progressing with its first clinical study with sepsis candidate Apta-1. The company has also ramped up activities t... |
| 06.03.2023 | Third cohort completed in Aptahem’s FIH study | Third cohort completed in Aptahem’s FIH study
Mon, Mar 06, 2023 17:12 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today... |
| 28.02.2023 | BioStock Article: Further steps in Aptahem's phase I study | BioStock Article: Further steps in Aptahem's phase I study
Tue, Feb 28, 2023 09:36 CET Report this content
At the end of December 2022, biotech company Aptahem announced the completion of cohort 1 in healthy volunteers for the phase I study... |
| 14.02.2023 | Third cohort in Aptahem’s FIH study initiated | Third cohort in Aptahem’s FIH study initiated
Tue, Feb 14, 2023 16:34 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today... |
| 10.02.2023 | Second cohort in Aptahem’s FIH study performed and approved by the ethics committee | Second cohort in Aptahem’s FIH study performed and approved by the ethics committee
Fri, Feb 10, 2023 14:07 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory di... |
| 29.12.2022 | First cohort dosed in Aptahem’s FIH study | First cohort dosed in Aptahem’s FIH study
Thu, Dec 29, 2022 11:46 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today tha... |
| 22.12.2022 | Newsletter 2022 | Newsletter 2022
Thu, Dec 22, 2022 13:26 CET Report this content
CEO comments
The year 2022 can be summarized in great progress for Aptahem. We have taken several steps towards to goal to develop our lead candidate Apta-1 for acute, inflamma... |
| 14.12.2022 | First subjects dosed in Aptahem’s FIH study | First subjects dosed in Aptahem’s FIH study
Wed, Dec 14, 2022 14:14 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today t... |
| 05.12.2022 | First subjects screened in Aptahem’s FIH study with Apta-1 | First subjects screened in Aptahem’s FIH study with Apta-1
Mon, Dec 05, 2022 15:54 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, an... |
| 01.12.2022 | Aptahem’s CEO interviewed during the Biotechgate conference | Aptahem’s CEO interviewed during the Biotechgate conference
Thu, Dec 01, 2022 08:48 CET Report this content
Mikael Lindstam, CEO at Aptahem, was interviewed during the Biotechgate digital partnering conference. In the video he describes the... |
| 01.12.2022 | Aptahem reports added positive and significant biological effect in an extended Corona virus-induced acute lung injury model treated with Apta-1 | Aptahem reports added positive and significant biological effect in an extended Corona virus-induced acute lung injury model treated with Apta-1
Thu, Dec 01, 2022 15:16 CET Report this content
Aptahem can today announce that the Toronto tea... |
| 29.11.2022 | Newsletter November 2022 | Newsletter November 2022
Tue, Nov 29, 2022 11:42 CET Report this content
CEO comments
We have now, after hard work and a great team work, taken our lead candidate Apta-1 into clinical phase. It feels well deserved considering everyone’s fan... |
| 28.11.2022 | Nomination committee for Aptahem Annual General Meeting 2023 | Nomination committee for Aptahem Annual General Meeting 2023
Mon, Nov 28, 2022 09:21 CET Report this content
Aptahem’s nomination committee for the AGM next year has held a meeting. The nomination committee consists of three members represe... |
| 10.11.2022 | Aptahem receives full regulatory approval to start the FIH study with Apta-1 | Aptahem receives full regulatory approval to start the FIH study with Apta-1
Thu, Nov 10, 2022 18:31 CET Report this content
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases ... |
| 19.09.2022 | Aptahem submit regulatory approval to initiate clinical phase 1 study | Aptahem submit regulatory approval to initiate clinical phase 1 study
Mon, Sep 19, 2022 15:42 CET Report this content
Aptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Net... |
| 23.06.2022 | Aptahem confirms that lead candidate Apta-1 shows very good tolerability in the GLP tox studies | Aptahem confirms that lead candidate Apta-1 shows very good tolerability in the GLP tox studies
Thu, Jun 23, 2022 08:43 CET Report this content
Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Prac... |
| 01.06.2022 | Aptahem appoints Ingela Hallberg as new CMO | Aptahem appoints Ingela Hallberg as new CMO
Wed, Jun 01, 2022 08:16 CET Report this content
Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has ... |
| 17.05.2022 | Aptahem enters agreement with international clinical CRO for phase 1 studies with Apta-1 | Aptahem enters agreement with international clinical CRO for phase 1 studies with Apta-1
Tue, May 17, 2022 11:14 CET Report this content
Aptahem (publ) announces today that the company has signed an agreement with the clinical contract rese... |
| 09.05.2022 | Aptahem enters new consortium financed by the KK Foundation | Aptahem enters new consortium financed by the KK Foundation
Mon, May 09, 2022 15:41 CET Report this content
Aptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzza... |
| 07.03.2022 | Aptahem reports prepared GMP certified Apta-1 for preparation of clinical studies | Aptahem reports prepared GMP certified Apta-1 for preparation of clinical studies
Mon, Mar 07, 2022 09:50 CET Report this content
Aptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug can... |
| 21.02.2022 | Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1 | Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1
Mon, Feb 21, 2022 13:47 CET Report this content
Aptahem can today announce that in addition to previously reported p... |
| 16.02.2022 | Aptahem receives patent protection in Japan for patent family 2 | Aptahem receives patent protection in Japan for patent family 2
Wed, Feb 16, 2022 10:57 CET Report this content
Aptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese... |
| 31.01.2022 | Aptahem appoints CMC Director | Aptahem appoints CMC Director
Mon, Jan 31, 2022 13:33 CET Report this content
Aptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as apt... |
| 13.01.2022 | Aptahem appoints new COO | Aptahem appoints new COO Thu, Jan 13, 2022 11:24 CET
Aptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the ph... |
| 07.01.2022 | Aptahem signs start up agreement with international clinical CRO for phase 1 studies with Apta-1 | Aptahem signs start up agreement with international clinical CRO for phase 1 studies with Apta-1 Fri, Jan 07, 2022 08:58 CET
Aptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement,... |
| 17.12.2021 | Idogen carries out a fully guaranteed rights issue of units of approximately SEK 50.4 million and brings forward the announcement of the year-end report for 2021 | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN... |
| 17.12.2021 | Idogen carries out a fully guaranteed rights issue of units of approximately SEK 50.4 million and brings forward the announcement of the year-end report for 2021 | Idogen carries out a fully guaranteed rights issue of units of approximately SEK 50.4 million and brings forward the announcement of the year-end report for 2021 Fri, Dec 17, 2021 08:21 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRE... |
| 02.12.2021 | Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied | Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied Thu, Dec 02, 2021 16:38 CET
Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent pr... |
| 03.11.2021 | Aptahem has started the production of GMP certified Apta-1 for clinical trials | Aptahem has started the production of GMP certified Apta-1 for clinical trials Wed, Nov 03, 2021 08:47 CET
Aptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has st... |
| 29.10.2021 | Aptahem announces positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1 | Aptahem announces positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1 Fri, Oct 29, 2021 08:42 CET
Aptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studi... |
| 29.09.2021 | Aptahem receives Turkish patent for the protection of patent family 2 | Aptahem receives Turkish patent for the protection of patent family 2 Wed, Sep 29, 2021 10:40 CET
Aptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe.... |
| 08.09.2021 | Aptahem organizes an online Sepsis seminar on World Sepsis Day 13 September | Aptahem organizes an online Sepsis seminar on World Sepsis Day 13 September Wed, Sep 08, 2021 08:56 CET
Aptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company's main candidate, is under de... |
| 07.09.2021 | Aptahem’s collaboration with Örebro University defines a previously not shown unique modulation mechanism on coagulation and inflammation from Apta-1 | Aptahem’s collaboration with Örebro University defines a previously not shown unique modulation mechanism on coagulation and inflammation from Apta-1 Tue, Sep 07, 2021 14:39 CET
Aptahem can today announce that further studies with Örebro Un... |
| 07.09.2021 | Aptahem receives patent protection in USA for patent family 2 | Aptahem receives patent protection in USA for patent family 2 Tue, Sep 07, 2021 08:48 CET
Aptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Tradema... |
| 01.09.2021 | Aptahem receives European patent for the protection of patent family 2 | Aptahem receives European patent for the protection of patent family 2 Wed, Sep 01, 2021 08:48 CET
Aptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucle... |
| 05.08.2021 | Aptahem’s lead candidate Apta-1 preliminary does not show any toxicity in the GLP tox studies | Aptahem’s lead candidate Apta-1 preliminary does not show any toxicity in the GLP tox studies Thu, Aug 05, 2021 08:42 CET
Aptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary sh... |
| 05.08.2021 | Aptahem : lead candidate Apta-1 preliminary does not show any toxicity in the GLP tox studies | Aptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary show positive results. The studies are the final part of the preclinical program before an application to start clinical stu... |
| 22.12.2020 | BioStock: Aptahem's wish list for next year's Christmas | BioStock published an article on 22 December 2020 about Aptahem, which can be read in full below.
Aptahem, which is developing an emergency medicine for the treatment of sepsis, carried out an oversubscribed rights issue in October. During ... |
